Document:

exv4w3

 

Exhibit 4.3

Deutsche Bank

Aktiengesellschaft

	 	 	 
	Date:

	 	June 24, 2005
	 
	 	 
	To:

	 	Orbimage Holdings Inc.
	 
	 	 
	Attention:

	 	Swaps Documentation Department
	Facsimile no.:

	 	1 703 480 7544
	 
	 	 
	Our Reference:

	 	Global No. N397243N/N397122N
	 
	 	 
	Re:

	 	Interest Rate Swap Transaction

Ladies and Gentlemen:

The purpose of this letter agreement is to set forth the terms and conditions of the Transaction
entered into between Deutsche Bank AG (“DB AG”) and Orbimage Holdings Inc. (“Counterparty”) on the
Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation”
as referred to in the Agreement specified below.

  The definitions and
    provisions contained in the 2000 ISDA Definitions (the “Definitions”)
    as published by the International Swaps and Derivatives Association, Inc.
    are incorporated by reference herein. In the event of any inconsistency between
    the Definitions and this Confirmation, this Confirmation will govern. 

For the purpose of this Confirmation, all references in the Definitions or the Agreement to a
“Swap Transaction” shall be deemed to be references to this Transaction.

	1.	 	This Confirmation evidences a complete and binding agreement between you and us as to the
terms of
the Transaction to which this Confirmation relates. This Confirmation, together with all other
documents referring to the ISDA Form (as defined below) (each a “Confirmation”) and confirming
transactions (each a “Transaction”) entered into between us (notwithstanding anything to the
contrary
in a Confirmation) shall supplement, form part of, and be subject to an agreement in the form
of a 1992
ISDA Master Agreement (Multicurrency-Cross Border) (New York law version) (the “ISDA Form”)
as if we had both executed an agreement in such form on the Trade Date of the first such
Transaction
between us (the “Agreement”) (A) with the Schedule thereto (i) specifying that (a) the
governing law is
the laws of the State of New York without reference to choice of law doctrine and (b) the
Termination
Currency is U.S. Dollars; (ii) incorporating the amendment to the definition of “lndemnifiable
Tax”
contained in (page 48 of) the “User’s Guide to the 1992 ISDA Master Agreements”; and (iii)
amending
Section 13(b) of the ISDA Form by (x) deleting in the second line of subparagraph (i) thereof
the word
“non-” and (y) deleting the final paragraph thereof; and (B) with any other modifications or
additions
to the ISDA Form set forth below. All provisions contained or incorporated by reference in
that
agreement will govern this Confirmation and in the event of any inconsistency between the terms
of
this Confirmation and the terms of that agreement, this Confirmation will prevail for the
purposes of
this Transaction.
	 
	2.	 	The terms of the particular Transaction to which this Confirmation relates are as follows:-

    	 	 	 	 
	
	Notional Amount: 	 	Initially, $250,000,000, provided, that
          if the
	 
	 	 	outstanding Note balance is reduced for
          any reason

 

 

    	 	 	 	 	 	 	 
	 
	 	 	 	(other
            than pursuant to an event of default under the Indenture), then either
            Counterparty 

	 
	 	 	 	shall
            notify DBAG, in writing of such reduction, or DBAG shall notify Counterparty,
            in writing of 

	 
	 	 	 	such
            reduction. Upon receipt of notice, either party has the option to
            reduce the outstanding 

	 
	 	 	 	Notional
            Amount proportionally to reflect such new Note balance on the third
            Business Day following 

	 
	 	 	 	such
            notice. Upon such election of reduction by either party, the Calculation
            Agent shall determine 

	 
	 	 	 	on
            the third Business Day following receipt of such notification the
            termination payment payable by 

	 
	 	 	 	one
            party to the other party hereto as the amount that would be payable
            in accordance with Section 

	 
	 	 	 	6(e)
            (ii) of the Agreement as if such reduction was a Terminated Transaction
            with a hypothetical 

	 
	 	 	 	Notional
            Amount equal to the reduction and otherwise having the same terms
            as this Transaction, the 

	 
	 	 	 	third
            Business Day following receipt of such notification was the Early
            Termination Date and 

	 
	 	 	 	Counterparty
            was the sole Affected Party. The termination amount payable by one
            party to the other 

	 
	 	 	 	party
            hereto shall be paid on the fifth Business Day following receipt of
            such notification. 

	 
	 	 	 	 	 	 
	 
	 	Trade Date: 	 	June 22,
            2005 

	 
	 	 	 	
	
	

	 
	 	Effective Date: 	 	June 29,
            2005 

	 
	 	 	 	
	
	

	 
	 	Termination Date: 	 	July 1,
            200S 

	 
	 	 	 	
	
	

	Fixed Amounts:	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	Fixed Rate Payer: 	 	Counterparty
          

	 
	 	 	 	
	
	

	 	 	Fixed Rate Payer 	 	 
	 
	 	Payment Dates: 	 	The
            1st day of January and July of each year, 

	 
	 	 	 	commencing
            January 1, 2006, through and including the 

	 
	 	 	 	Termination
            Date, subject to no adjustment 

	 
	 	 	 	
	
	

	 
	 	Fixed Rate: 	 	4.25%
	
	

	 
	 	 	 	 	 	 
	 
	 	Fixed Rate Day 	 	30/360
	 	 
	 
	 	Count Fraction: 	 	
          

	 
	 	 	 	 	 	 
	Floating Amounts:	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	Floating Rate Payer:	 	DBAG 
	 	 
	 
	 	 	 	 	 	 
	 
	 	Floating Rate Payer	 	 	 	 
	 
	 	Payment Dates: 	 	The
            1st day of January and July of each year, 

	 
	 	 	 	commencing
            January 1, 2006, through and including 

	 
	 	 	 	the
            Termination Date, subject to no adjustment 

	 
	 	 	 	 	 	 
	 
	 	Floating Rate for initial	 	 	 	 
	 
	 	Calculation/Compounding 
Period: 	 	To
            be determined 

2

 

    	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	Floating Rate Option: 	 	the
            greater of 3.00% or LIBOR-BBA 

	 
	 	 	 	
	
	

	 
	 	Designated Maturity: 	 	6 months
          

	 
	 	 	 	
	
	

	 
	 	Spread: 	 	None
          

	 
	 	 	 	 	 	 
	 
	 	Floating Rate Day

          Count Fraction: 	 	
30/360
	 	 
	 
	 	 	 	 	 	 
	 
	 	Reset Dates: 	 	The
            first Business Day in each Calculation Period or 

	 
	 	 	 	Compounding
            Period, if Compounding is applicable. 

	 
	 	 	 	 	 	 
	 
	 	Compounding: 	 	Inapplicable
          

	 
	 	 	 	
	
	

	Business Days:	 	New
            York 

3. Additional Termination Events: The following shall be Additional Termination Events
with Counterparty as the sole Affected Party:

(i) if Counterparty does not, on or before June 29, 2005, issue $250,000,000 senior floating rate
notes due 2012, pursuant to an indenture to be executed in connection therewith, with Counterparty
as issuer, and the
Bank of New York, as trustee, substantially on the terms of the draft indenture dated June  , 2005
(the
“Indenture”);

(ii) if DBAG is not, on or before July 7, 2005, secured equally and ratably with the note holders
under the security agreement to be entered into pursuant to the Indenture, substantially in the
form of the draft dated June 21, 2005 (the “Security Agreement”), provided that such secured
interest in favor of DBAG shall be limited to $10,000,000. The Security Agreement shall also be a
Credit Support Document for the purposes of the Agreement;

(iii) if DBAG is not the beneficiary of any guarantee issued in favor of the note holders;

(iv) if any collateral
under the Security Agreement is released at any time, unless DBAG shall have
consented in writing prior to such release (such consent not to be unreasonably withheld), provided
such release does not have a material adverse affect on DBAG (as determined by DBAG in its sole
discretion); provided further that a release of collateral permitted under Section 10.01 of the
Indenture shall be permitted without DBAG’s consent and shall not be an Additional Termination
Event hereunder;

(v) the occurrence of (x) any default in the payment of interst, principal or premium under the
Notes (after the expiration of any applicable grace period) or (y) (ii) any default, event of
default or other similar condition or event under the Indenture or the Security Agreement which has
resulted in the Notes being declared due and payable prior to the time it would otherwise have been
due and payable under the terms therof;

(vi) if and provision of the Indenture with respect to collateral, or any application of proceeds
thereof, or any provision of Security Agreement is amended without the consent of DBAG (which
consent shall not be unreasonably withheld) provided that such amendment has a material adverse
affect on the rights of DBAG.

Default Rate: Subsection (b) of the definition of Applicable Rate in Section 14 of the Agreement
shall be amended by adding the following to the end thereof:

3

 

“provided that the Applicable Rate with respect to any amount owed to DBAG under Section 6(e)(ii)
where Counterparty is the Defaulting Party or Affected Party shall be at a rate per annum equal to
the cost (without proof or evidence of any actual cost) to DBAG (as certified by it) if it were to
fund or of funding the relevant amount plus 9.5% per annum.”

(vii) Set-off. Section 6 of this Agreement is amended by the addition of the following Section
6(f):

"(f) Upon the designation of any Early Termination Date, the party that is not the
Defaulting Party or Affected Party (“X”) may, without prior notice to the Defaulting or
Affected Party (“Y”), set off any sum or obligation (whether or not arising under this
Agreement, whether matured or unmatured, whether or not contingent and irrespective of the
currency, place of payment or booking office of the sum or obligation) owed by Y to X or
any Affiliate of X (the “X Set Off Amount”) against any sum or obligation (whether or not
arising under this Agreement, whether matured or unmatured, whether or not contingent and
irrespective of the currency, place of payment or booking office of the sum or obligation)
owed by X or any Affiliate of X to Y (the “Y Set Off Amount”). X will give notice to the
other party of any set off effected under this Section 6(f).

For this purpose, either the X Set Off Amount or the Y Set Off Amount (or the relevant
portion of such set off amounts) may be converted by X into the currency in which the other
set off amount is denominated at the rate of exchange at which X would be able, acting in a
reasonable manner and in good faith, to purchase the relevant amount of such currency.

If a sum or obligation is unascertained, X may in good faith estimate that obligation and
set-off in respect of the estimate, subject to the relevant party accounting to the other
when the obligation is ascertained.

Nothing in this Section 6(f) shall be effective to create a charge or other security interest.
This Section 6(f) shall be without prejudice and in addition to any right of set-off,
combination of accounts, lien or other rights to which any party is at any time otherwise
entitled (whether by operation of law, contract or otherwise).”

4. Account Details:

	 	 	 	 	 	 	 
	

	 	Account Details for DBAG:	 	 	 	 
	 
	 	 	 	 	 	 
	

	 	     USD DBAG Payment Instructions:	 	 	 	 
	

	 	     Account With:
	 	 

	

	 	     SWIFT Code:
	 	 

	

	 	     Favor Of:
	 	 

	

	 	     Account Number:
	 	 
	 
	 	 	 	 	 	 
	

	 	Account Details for Counterparty:	 	 	 	 

PLEASE PROVIDE AT YOUR EARLIEST CONVENIENCE

5. Offices:

     The Office of DBAG for this Transaction is New York.

     The Office of Counterparty for this Transaction is Dulles.

6. Calculation Agent:                    DBAG

4

 

7. Representations

Counterparty, if it is a nonresident alien individual, foreign corporation, foreign partnership,
foreign trust, or foreign estate, represents that it is a foreign person for purposes of US
Treasury regulations relating to information reporting and backup withholding.

Each party will be deemed to represent to the other party on the date on which it enters into
this Transaction that (absent a written agreement between the parties that expressly imposes
affirmative obligations to the contrary for this Transaction):-

(i) Non-Reliance. It is acting for its own account, and it has made its own independent decisions
to enter into this Transaction and as to whether this Transaction is appropriate or proper for it
based upon its own judgment and upon advice from such advisers as it has deemed necessary. It is
not relying on any communication (written or oral) of the other party as investment advice or as a
recommendation to enter into this Transaction; it being understood that information and
explanations related to the terms and conditions of this Transaction shall not be considered
investment advice or a recommendation to enter into this Transaction. No communication (written or
oral) received from the other party shall be deemed to be an assurance or guarantee as to the
expected results of this Transaction.

(ii) Assessment and Understanding. It is capable of assessing the merits of and understanding (on
its own behalf or through independent professional advice), and understands and accepts, the terms,
conditions and risks of this Transaction. It is also capable of assuming, and assumes, the risks of
this Transaction.

(iii) Status of Parties. The other party is not acting as a fiduciary for, or an adviser to it
in respect of this Transaction.

5

 

8. Please confirm that the foregoing correctly sets forth the terms of our agreement by having
an authorized officer sign this Confirmation and return it via facsimile or e-mail to:

     Attention: Derivative Documentation

     Telephone: 44 20 7547 4755

     Facsimile: 44 20 7545 9761

     E-mail: Derivative.Documentation@db.com

This message will be the only form of Confirmation dispatched by us. If you wish to exchange
hard copy forms of this Confirmation, please contact us.

Yours sincerely,

Deutsche Bank AG

  By: /s/ Gaby Bolton

  Name: Gaby Bolton
  Authorized
Signatory

  By: /s/ Jamie Hunt

  Name: Jamie Hunt
  Authorized
Signatory

Confirmed as of the date first written above:

Orbimage Inc (main)

	 	 	 
	By:
	 /s/ William Lee Warren	 
	

	 	 
	Name:
	 William Lee Warren	 
	

	 	 
	Title:
	 Vice President, General Counsel and Secretary	 
	

	 	 

6exv10w1

 

EXHIBIT 10.1

Human Genome Sciences, Inc.

Amended and Restated 2000 Stock Incentive Plan

Restricted Stock Agreement

Award Recipient: 

Number of Shares: 

     This Agreement (the “Agreement”) evidences the award of ___restricted shares (each, an
“Award Share,” and collectively, the “Award Shares”) of the Common Stock of Human Genome Sciences,
Inc. (the “Common Stock”), a Delaware corporation (the “Company”), granted to you, ___,
effective as of ___(the “Grant Date”), pursuant to the Human Genome Sciences, Inc.
Amended and Restated 2000 Stock Incentive Plan, as amended (the “Plan”) and conditioned upon your
agreement to the terms described below. All of the provisions of the Plan are expressly
incorporated into this Agreement.

     1.      Terminology. Capitalized words used in this Agreement not defined above are
defined in the Glossary at the end of the Agreement, or as otherwise provided herein.

     2.      Vesting. All of the Award Shares are nonvested and forfeitable as of the Grant
Date. So long as your Service with the Company is continuous from [your first day of active
employment with the Company][the Grant Date] through the applicable date upon which vesting is
scheduled to occur, ___percent of the Award Shares will vest and become nonforfeitable on
___, 20___, an additional ___percent of the Award Shares will vest and become nonforfeitable
on ___, 20___, and the remaining ___percent of the Award Shares will vest and become
nonforfeitable on ___, 20___. Unless otherwise determined by the Administrator, none of the
nonvested and forfeitable Award Shares will become vested and nonforfeitable after your Service
with the Company ceases. [Include the following for executives who participate in the Key
Executive Severance Plan: Notwithstanding the foregoing, unless earlier forfeited, vesting of the
Award Shares will accelerate so that the unvested portion of the Award Shares will become one
hundred percent vested and nonforfeitable as of the Effective Date of a Change of Control, as those
terms are defined in the Key Executive Severance Plan.]

     3.      Termination of Employment or Service. If your Service with the Company ceases for
any reason, all Award Shares that are not then vested and nonforfeitable will be immediately
forfeited to the Company upon such cessation for no consideration, except as provided in Section 2.

     4.      Restrictions on Transfer.

               (a)      Until an Award Share becomes vested and nonforfeitable, it may not be assigned,
transferred, pledged, hypothecated or disposed of in any way (whether by operation of law or
otherwise) and shall not be subject to execution, attachment or similar process.

               (b)      The Company shall not be required to (i) transfer on its books any Award Shares that have
been sold or transferred in contravention of this Agreement or (ii) treat as the owner of Award
Shares, or otherwise accord voting, dividend or liquidation rights to, any transferee to whom Award
Shares have been transferred in contravention of this Agreement.

     5.      Stock Certificates. You are reflected as the owner of record of the Award Shares
as of the Grant Date on the Company’s books. The Company will hold the share certificates for
safekeeping, or otherwise retain the Award Shares in uncertificated book entry form, until the
Award Shares become vested and nonforfeitable. Until the Award Shares become vested and
nonforfeitable, any share certificates representing such shares will include a legend to the effect
that you may not sell, assign, transfer, pledge, or hypothecate the Award Shares. All regular cash
dividends on the Award Shares held by the Company will be paid directly to you. As soon as
practicable after vesting of the Award Shares, the Company will deliver a share certificate to you,
or deliver shares electronically or in certificate form to your designated broker on your behalf,
for such vested Award Shares.

 

 

     6.      Tax Election and Tax Withholding.

               (a)      The Company shall have the right to deduct from any compensation or any other payment of
any kind (including withholding the issuance of shares of Common Stock) due you the amount of any
federal, state, local or foreign taxes required by law to be withheld as a result of the grant or
vesting of the Award Shares in whole or in part; provided, however, that the value of the shares of
Common Stock withheld may not exceed the statutory minimum withholding amount required by law. In
lieu of such deduction, the Company may require you to make a cash payment to the Company equal to
the amount required to be withheld. If you do not make such payment when requested, the Company
may refuse to issue any Common Stock certificate under this Agreement until arrangements
satisfactory to the Administrator for such payment have been made.

               (b)      You hereby acknowledge that you have been advised by the Company to seek independent tax
advice from your own advisors regarding the availability and advisability of making an election
under Section 83(b) of the Internal Revenue Code of 1986, as amended, and that any such election,
if made, must be made within 30 days of the Grant Date. You expressly acknowledge that you are
solely responsible for filing any such Section 83(b) election with the appropriate governmental
authorities, irrespective of the fact that such election is also delivered to the Company. You may
not rely on the Company or any of its officers, directors or employees for tax or legal advice
regarding this award. You acknowledge that you have sought tax and legal advice from your own
advisors regarding this award or have voluntarily and knowingly foregone such consultation.

     7.      Adjustments and Corporate Reorganizations.

               (a)      Subject to any required action by the Company (which will be promptly taken) or its
shareholders, and subject to the provisions of the Delaware General Corporation Law, if the
outstanding Common Stock are increased or decreased or changed into or exchanged for a different
number or kind of security by reason of any recapitalization, reclassification, stock split,
reverse stock split, combination of shares, exchange of shares, stock dividend, or other
distribution payable in capital stock, or other increase or decrease in such Common Stock is
effected without receipt of consideration by the Company occurring after the Grant Date, a
proportionate and appropriate adjustment shall be made to the number of shares of Common Stock
underlying the grant of Award Shares pursuant to this Agreement (the “Award”), so that your
proportionate interest immediately following such event shall, to the extent practicable, be the
same as immediately before such event. No fractional Award Shares will result from any such
adjustments. The Administrator will make the adjustments required by this Section 7(a) and its
determination will be final, binding and conclusive. The terms and conditions of this Agreement
shall apply with equal force to any additional and/or substitute securities received by you in
exchange for, or by virtue of your ownership of, the Award Shares, whether as a result of any
spin-off, stock split-up, stock dividend, stock distribution, other reclassification of the Common
Stock of the Company, or similar event, except as otherwise determined by the Administrator.

               (b)      Upon the dissolution or liquidation of the Company, or upon a reorganization, merger, or
consolidation of the Company as a result of which the outstanding securities of the class of
securities then subject to the Award are changed into or exchanged for cash or property or
securities not of the Company’s issue, or any combination thereof, or upon a sale of substantially
all the property of the Company to, or the acquisition of shares of Common Stock representing more
than eighty percent (80%) of the voting power of the shares of Common Stock then outstanding by,
another corporation or person, then the rights of the Company under this Agreement shall inure to
the benefit of the Company’s successor, and this Agreement shall apply to the securities or other
property received upon such event in the same manner and to the same extent as the Award Shares.

     8.      Non-Guarantee of Employment or Service Relationship. Nothing in the Plan or this
Agreement shall alter your at-will or other employment status or other service relationship with
the Company, nor be construed as a contract of employment or service relationship between the
Company and you, or as a contractual right of you to continue in the employ of, or in a service
relationship with, the Company for any period of time, or as a limitation of the right of the
Company to discharge you at any time with or without cause or notice and whether or not such
discharge results in the forfeiture of any nonvested and forfeitable Award Shares or any other
adverse effect on your interests under the Plan.

-2-

 

     9.      Rights as Stockholder. Except as otherwise provided in this Agreement with respect
to the nonvested and forfeitable Award Shares, you are entitled to all rights of a stockholder of
the Company, including the right to vote the Award Shares and receive dividends and/or other
distributions declared on the Award Shares.

     10.      The Company’s Rights. The existence of the Award Shares shall not affect in any
way the right or power of the Company or its stockholders to make or authorize any or all
adjustments, recapitalizations, reorganizations or other changes in the Company’s capital structure
or its business, or any merger or consolidation of the Company, or any issue of bonds, debentures,
preferred or other stocks with preference ahead of or convertible into, or otherwise affecting the
Common Stock or the rights thereof, or the dissolution or liquidation of the Company, or any sale
or transfer of all or any part of the Company’s assets or business, or any other corporate act or
proceeding, whether of a similar character or otherwise.

     11.      Notices. All notices and other communications made or given pursuant to this
Agreement shall be in writing and shall be sufficiently made or given if hand delivered or mailed
by certified mail, addressed to you at the address contained in the records of the Company, or
addressed to the Administrator, care of the Company for the attention of its Corporate Secretary at
its principal executive office or, if the receiving party consents in advance, transmitted and
received via telecopy or via such other electronic transmission mechanism as may be available to
the parties.

     12.      Entire Agreement. This Agreement contains the entire agreement between the
parties with respect to the Award Shares granted hereunder. Any oral or written agreements,
representations, warranties, written inducements or other communications made prior to the
execution of this Agreement with respect to the Award Shares granted hereunder shall be void and
ineffective for all purposes.

     13.      Amendment. This Agreement may be amended from time to time by the Administrator
in its discretion; provided, however, that this Agreement may not be modified in a
manner that would have a materially adverse effect on the Award Shares as determined in the
discretion of the Administrator, except as provided in the Plan or in a written document signed by
each of the parties hereto.

     14.      Conformity with Plan. This Agreement is intended to conform in all respects with,
and is subject to all applicable provisions of, the Plan. Inconsistencies between this Agreement
and the Plan shall be resolved in accordance with the terms of the Plan. In the event of any
ambiguity in this Agreement or any matters as to which this Agreement is silent, the Plan shall
govern. A copy of the Plan is available upon request to the Administrator.

     15.      Governing Law. The validity, construction and effect of this Agreement, and of any
determinations or decisions made by the Administrator relating to this Agreement, and the rights of
any and all persons having or claiming to have any interest under this Agreement, shall be
determined exclusively in accordance with the laws of the State of Delaware, without regard to its
provisions concerning the applicability of laws of other jurisdictions. Any suit with respect
hereto will be brought in the federal or state courts in the district which include the city or
town in which the Company’s principal executive office is located, and you hereby agree and submit
to the personal jurisdiction and venue thereof.

     16.      Headings. The headings in this Agreement are for reference purposes only and
shall not affect the meaning or interpretation of this Agreement.

     17.      Counterparts. This Agreement may be executed in counterparts, each of which shall
be deemed an original, but all of which together shall constitute one and the same instrument.

-3-

 

GLOSSARY

               (a)      “Administrator” means the Board of Directors of Human Genome Sciences, Inc. or such
committee or committees appointed by the Board to administer the Plan.

               (b)      “Affiliate” means any entity, whether now or hereafter existing, which controls, is
controlled by, or is under common control with Human Genome Sciences, Inc. (including but not
limited to joint ventures, limited liability companies and partnerships). For this purpose,
“control” means ownership of 50% or more of the total combined voting power or value of all classes
of stock or interests of the entity.

               (c)      “Company” means Human Genome Sciences, Inc. and its Affiliates, except where the context
otherwise requires.

               (d)      “Key Executive Severance Plan” means the Human Genome Sciences, Inc. Key Executive
Severance Plan, as adopted by the Company and as may be amended or replaced at any time.

               (e)      “Service” means your employment or other service relationship with the Company and its
Affiliates. Your Service will be considered to have ceased with the Company and its Affiliates if,
immediately after a sale, merger or other corporate transaction, the trade, business or entity with
which you are employed or otherwise have a service relationship is not Human Genome Sciences, Inc.
or an Affiliate of Human Genome Sciences, Inc.

               (f)      “You” or “Your” means the recipient of the Award Shares as reflected in the first
paragraph of this Agreement. Whenever the word “you” or “your” is used in any provision of this
Agreement under circumstances where the provision should logically be construed, as determined by
the Administrator, to apply to the estate, personal representative, or beneficiary to whom the
Award Shares may be transferred by will or by the laws of descent and distribution, the words “you”
and “your” shall be deemed to include such person.

-4-

 

     IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly
authorized officer.

	 	 	 	 	 
	 	HUMAN GENOME SCIENCES,
INC.

 	 
	 	By:  	
 	 
	 	 	 	 
	 	 	 	 
	 
	 	 	 
	 	Date:  	
 	 
	 	 	 	 
	 	 	 	 
	 

The undersigned hereby acknowledges that he/she has carefully read this Agreement and agrees to be
bound by all of the provisions set forth herein. The undersigned hereby agrees to accept as
binding, conclusive, and final all decisions or interpretations of the Board of Directors or the
Administrator upon any questions arising under the Plan.

WITNESS:

	 	 	 	 
	 	 	 
	 
	 	[Name]

	 	 	 	 	 
	 	Date:  	
 	 
	 	 	 	 
	 	 	 
	 	Address:  	
 	 
	 	 	 	 
	 	 	 	 
	 

Enclosures:

	 	•	 	Prospectus for the Human Genome Sciences,
Inc.

Amended and Restated 2000 Stock Incentive Plan
	 
	 	•	 	Stock Power
	 
	 	•	 	Section 83(b) Notice and Sample Election Form

-5-

 

STOCK POWER

     FOR VALUE RECEIVED, the undersigned, ____________, hereby sells, assigns and transfers unto
Human Genome Sciences, Inc., a Delaware corporation (the “Company”), or its successor,
_________shares of common stock, par value $.01 per share, of the Company standing in my name
on the books of the Company, represented by Certificate No. _________, which is attached hereto,
and hereby irrevocably constitutes and appoints
__________________________________________as my attorney-in-fact to transfer the said
stock on the books of the Company with full power of substitution in the premises.

WITNESS:

	 	 	 	 
	 	 	 
	 
	 	 

	 	 	 	 	 
	 	Dated:  	
 	 
	 	 	 	 
	 

-6-

 

IMPORTANT TAX INFORMATION

INSTRUCTIONS REGARDING SECTION 83(b) ELECTIONS

	 	1.	 	The 83(b) Election is Irrevocable. The 83(b) Election is a voluntary election that is
available to you. It is your decision whether to file an 83(b) Election.
	 
	 	2.	 	The 83(b) Election Form must be filed with the Internal Revenue Service within 30 days of the
Grant Date; no exceptions to this rule are made.
	 
	 	3.	 	You must provide a copy of the 83(b) Election Form to the Corporate Secretary or other
designated officer of the Company. This copy should be provided to the Company at the same
time that you file your 83(b) Election Form with the Internal Revenue Service.
	 
	 	4.	 	In addition to making the filing under Item 2 above, you must attach a copy of your 83(b)
Election Form to your tax return for the taxable year that includes the Grant Date.
	 
	 	5.	 	If you make an 83(b) Election and later forfeit the Award Shares, you will not be entitled to
a refund of the taxes paid with respect to the gross income you recognized under the 83(b)
Election.
	 
	 	6.	 	You must consult your personal tax advisor before making an 83(b) Election. The attached
election forms are intended as samples only, they must be tailored to your circumstances and
may not be relied upon without consultation with a personal tax advisor.

-7-

 

SECTION 83(b) ELECTION FORM

Election Pursuant to Section 83(b) of the Internal Revenue Code to Include Property in Gross Income

in Year of Transfer

     The undersigned hereby makes an election pursuant to Section 83(b) of the Internal Revenue
Code with respect to the property described below and supplies the following information in
accordance with the regulations promulgated thereunder:

     1.      The name, address, and taxpayer identification number of the undersigned are:

               _______________________________

               _______________________________

               _______________________________

               ___-___-___

     2.      The property with respect to which the election is made is ____________shares of
Common Stock, par value $.01 per share, of Human Genome Sciences, Inc., a Delaware corporation (the
“Company”).

     3.      The date on which the property was transferred was ____________, the date on which the
taxpayer received the property pursuant to a grant of restricted stock.

     4.      The taxable year to which this election relates is calendar year 20___.

     5.      The property is subject to restrictions in that the property is not transferable and is
subject to a substantial risk of forfeiture until the taxpayer vests in the property. The taxpayer
will vest in ______percent of the shares of Common Stock on ____________, 20___, in an additional ___
percent of the shares on ____________, 20___, and in the remaining ___percent of the shares on
_________, 20___, provided the taxpayer is in the employ of the Company on such dates.

     6.      The fair market value at the time of transfer (determined without regard to any
restrictions other than restrictions which by their terms will never lapse) of the property with
respect to which this election is being made is $_________  per share; with a cumulative fair
market value of $____________. The taxpayer did not pay any amount for the property transferred.

     7.      A copy of this statement was furnished to Human Genome Sciences, Inc., for whom the
taxpayer rendered the services underlying the transfer of such property.

     8.      This election is made to the same effect, and with the same limitations, for purposes of
any applicable state statute corresponding to Section 83(b) of the Internal Revenue Code.

     The undersigned understands that the foregoing election may not be revoked except with the
consent of the Commissioner of Internal Revenue.

     Signed:___________________________

     Date:_____________________________

-8-

 

Letter for filing §83(b) Election Form

[Date]

CERTIFIED MAIL

RETURN RECEIPT REQUESTED

Internal Revenue Service Center

_______________________________

_______________________________

_______________________________

(the Service Center to which individual income tax return is filed)

	 	 	 
	Re:

	 	83(b) Election of [Name]

Social Security Number:       ______________________

 

Dear Sir/Madam:

     Enclosed is an election under §83(b) of the Internal Revenue Code of 1986, as amended, with
respect to certain shares of stock of Human Genome Sciences, Inc. that were transferred to me on
____________, 20___.

     Please file this election.

Sincerely,

____________________________

[Name]

     cc: Corporate Secretary of Human Genome Sciences, Inc.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00088-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00088-of-00352.parquet"}]]